Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cowen Downgrades ERYTECH Pharma to Market Perform From Outperform

10/26/2021 | 06:05am EST


ę MT Newswires 2021
All news about ERYTECH PHARMA S.A.
01/25European ADRs Move Lower in Tuesday Trading
MT
01/25Erytech announces presentation of results of two clinical trials of eryaspase in pancre..
AQ
01/24Erytech Pharma Says Phase 1 Study of Pancreatic Cancer Drug Showed 'Encouraging' Clinic..
MT
01/24Erytech Pharma Logs Encouraging Clinical Activity In Pancreatic Cancer Treatment Trial
MT
01/24ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Panc..
AQ
01/24ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in..
CI
01/03ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
AQ
01/03European ADRs Move Higher in Monday Trading
MT
2021European ADRs Nudge Lower in Tuesday Trading
MT
2021ERYTECH PHARMA S A : ANNOUNCES PRESENTATION OF RESULTS OF EXPANDED ACCESS PROGRAM IN ALL A..
PU
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Financials
Sales 2021 6,74 M 7,57 M 7,57 M
Net income 2021 -61,2 M -68,8 M -68,8 M
Net Debt 2021 16,1 M 18,1 M 18,1 M
P/E ratio 2021 -0,60x
Yield 2021 -
Capitalization 58,1 M 65,6 M 65,3 M
EV / Sales 2021 11,0x
EV / Sales 2022 6,50x
Nbr of Employees 196
Free-Float 67,5%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 1,87 €
Average target price 4,30 €
Spread / Average Target 129%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-11.60%67
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-12.11%50 700
BIONTECH SE-39.30%37 796